Thematic evaluation
Back to company overview

Regeneron Pharmaceuticals, Inc. (REGN)

September 06, 2024

Compared to: Vertex Pharmaceuticals, Inc. (VRTX) | Amgen, Inc. (AMGN) | Health Care Select Sector SPDR Fund (XLV)

Our reasoning

Regeneron appears moderately undervalued based on its strong financial performance, robust pipeline, and market leadership position in key therapeutic areas. The company's valuation multiples (P/E and EV/EBITDA) are below industry averages despite its superior profitability and growth prospects. Additionally, the potential for expansion in product indications and new market opportunities are not fully reflected in the current valuation.

Key takeaways
  • Regeneron is a leading biotechnology company with a strong financial position, characterized by high profitability, robust liquidity, and low debt levels.
  • The company's revenue growth is driven by the success of its key products, EYLEA HD and Dupixent, and its expansion into new markets.
  • Regeneron is investing heavily in R&D and commercialization, which is driving the increase in operating expenses and leading to a decline in profitability.
  • The company's cash flow from operations is decreasing, which could be a concern if it continues to decline.
  • Regeneron's financial flexibility will allow it to continue to pursue strategic opportunities and return capital to shareholders.
  • Key risks include the company's dependence on a few key products, intense competition in its key therapeutic areas, and the potential impact of increasing debt levels on its financial leverage and debt service coverage.
  • Regeneron's valuation is currently high, reflecting investor confidence in the company's growth potential and strong financial performance.
  • The company's stock price has generally outperformed the broader healthcare sector and its peers, but it has exhibited higher volatility than its benchmark and peers.
  • Overall, Regeneron appears to be a well-positioned biotechnology company with strong growth potential and a solid financial foundation. However, investors should be aware of the company's dependence on a few key products, intense competition, and regulatory challenges.
Undervalued
Ask a question about Regeneron Pharmaceuticals, Inc. (REGN)
Evaluation summary

  1. Company Overview:

    • Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for people with serious diseases. The company's business model is built on its proprietary VelociSuite technologies, particularly VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. This technology accelerates the traditional drug development process, enabling Regeneron to bring innovative therapies to market faster.
    • Regeneron's product portfolio includes several key marketed products, including EYLEA, EYLEA HD, Dupixent, Libtayo, Praluent, and Evkeeza. These products target a range of therapeutic areas, including ophthalmology, dermatology, oncology, and cardiovascular disease. The company's revenue is primarily driven by net product sales of these products, with EYLEA, Dupixent, and other Regeneron-discovered products contributing significantly to its top line.
    • Regeneron's target market consists of distributors, specialty pharmacies, and healthcare providers who treat patients with serious diseases. The company's products are primarily prescribed by specialists in ophthalmology, dermatology, oncology, and cardiology. Regeneron's key competitors include other biotechnology and pharmaceutical companies developing similar products or therapies, creating a highly competitive landscape.
    • For comparative analysis, we will be using the Health Care Select Sector SPDR Fund (XLV) as a benchmark to assess REGN's performance relative to the broader healthcare sector. We will also compare REGN to its industry peers, Vertex Pharmaceuticals, Inc. (VRTX) and Amgen, Inc. (AMGN), to understand its relative financial performance, growth potential, and risk profile.

  2. Financial Performance:

    • Regeneron has demonstrated strong financial performance in recent years, with consistent revenue growth driven by the success of its key products. Revenue has increased from $3.22 billion in 2023-09-30 to $3.55 billion in 2024-06-30, representing a 10% year-over-year growth. This growth is attributed to the successful launch of EYLEA HD, continued global growth of Dupixent, and higher Sanofi collaboration revenue.
    • The company's profitability has also been strong, with a high return on assets (ROA) and return on equity (ROE). ROA has remained consistently above 12% in recent quarters, indicating efficient asset utilization. ROE has also been consistently above 15%, suggesting effective capital deployment. However, profitability has declined slightly in recent quarters, likely due to increased operating expenses related to R&D and commercialization investments.
    • Regeneron's net profit margin has been consistently above 30% in recent quarters, indicating strong profitability. However, the margin has declined slightly from 33.77% in 2023-12-31 to 32.57% in 2024-06-30, likely due to increased operating expenses.
    • Compared to its peers, Regeneron has generally outperformed both VRTX and AMGN in terms of revenue growth and profitability. However, VRTX has shown stronger performance in the 3-year period, likely due to its strong performance in the early part of the period.

  3. Operational Efficiency:

    • Regeneron's balance sheet is characterized by a strong liquidity position, with a high current ratio and quick ratio. The current ratio has remained consistently above 5, indicating ample short-term liquidity. The quick ratio has also been consistently above 4, suggesting a strong ability to meet short-term obligations. However, both ratios have declined slightly in recent quarters, potentially due to increased working capital needs related to growth initiatives.
    • Regeneron's working capital management has been efficient, with a consistent positive working capital balance. However, the company has experienced a slight decline in working capital in recent quarters, potentially due to increased inventory levels or delayed collections.
    • Regeneron's cash flow from operations has been strong, with a consistent positive cash flow. However, the company has experienced a decline in operating cash flow in recent quarters, potentially due to increased R&D and commercialization investments.
    • Regeneron's free cash flow has also been strong, with a consistent positive free cash flow. However, the company has experienced a decline in free cash flow in recent quarters, potentially due to increased capital expenditures and R&D investments.
    • Regeneron's capital expenditures have been increasing in recent quarters, likely due to investments in new manufacturing facilities and infrastructure to support the growth of its product portfolio.
    • Regeneron has not paid dividends in recent years, but it has been actively repurchasing shares. The company's share repurchase program has been significant, with $3.631 billion remaining available as of June 30, 2024.
    • Compared to its peers, Regeneron has generally shown better operational efficiency, with higher ROA, ROE, and free cash flow margins. However, VRTX has shown stronger performance in some areas, particularly in terms of working capital management and asset utilization.

  4. Growth Opportunities:

    • Regeneron has several growth opportunities, including market expansion, M&A, R&D pipeline development, geographic expansion, and strategic focus areas.
    • The company is actively expanding its market reach by pursuing new indications for its existing products and developing new products for unmet medical needs. For example, Regeneron is seeking approval for Dupixent in chronic obstructive pulmonary disease (COPD), which could significantly expand its market reach.
    • Regeneron has a history of successful M&A activity, with recent acquisitions including Decibel Therapeutics, Inc. to expand its hearing disease pipeline. The company is actively seeking new acquisition opportunities to enhance its product portfolio and expand its therapeutic areas.
    • Regeneron has a robust R&D pipeline with over 35 programs in clinical development spanning several therapeutic areas. The company is investing heavily in R&D to develop new therapies for a range of diseases, including oncology, hematology, obesity, and genetics medicines.
    • Regeneron is expanding its geographic reach by pursuing regulatory approvals and commercialization opportunities in new markets. The company is actively expanding its presence in Europe, Asia, and other regions to capitalize on the global demand for innovative therapies.
    • Regeneron's strategic focus areas include developing best-in-class antibodies, expanding its product portfolio, and advancing its pipeline. The company is committed to delivering innovative therapies to patients and achieving sustainable growth.
    • Regeneron has a strong track record of executing its strategic plans, with consistent revenue growth and successful product launches. The company's management team has demonstrated a strong ability to navigate the complex biotechnology industry and achieve its goals.

  5. Risks and Threats:

    • Regeneron faces several risks and threats, including dependence on a few key products, intense competition, regulatory challenges, manufacturing and supply chain challenges, intellectual property disputes, legal and compliance risks, and macroeconomic uncertainties.
    • Regeneron's revenue is heavily concentrated in a few key products, including EYLEA, EYLEA HD, and Dupixent. Any decline in the sales of these products could significantly impact the company's financial performance.
    • The biotechnology industry is highly competitive, with numerous companies developing similar products or therapies. Regeneron faces intense competition from both branded and generic/biosimilar products, which could impact its market share and profitability.
    • The regulatory environment for biotechnology companies is complex and evolving. Regeneron faces significant challenges in obtaining and maintaining product approvals from the FDA and other global regulatory bodies. Any delays or setbacks in regulatory approvals could impact the company's growth and profitability.
    • Regeneron's manufacturing and supply chain are subject to various risks, including capacity constraints, regulatory compliance issues, and disruptions due to natural disasters or pandemics. Any disruptions in manufacturing or supply could impact the company's ability to meet demand and maintain its financial performance.
    • Regeneron's intellectual property is critical to its success. The company faces potential risks related to patent infringement lawsuits and the loss of market exclusivity. Any loss of intellectual property protection could impact the company's competitive advantage and profitability.
    • Regeneron faces legal and compliance risks, including government investigations and product liability claims. Any legal or compliance issues could impact the company's reputation, financial performance, and growth prospects.
    • Macroeconomic uncertainties, such as inflation, interest rate hikes, and geopolitical instability, could impact the company's financial performance and growth prospects.

  6. Valuation Analysis:

    • Regeneron's valuation is currently high, with a P/E ratio of 25.00 and an EV/EBITDA ratio of 25.00. These ratios suggest that investors are willing to pay a premium for the company's growth potential and strong financial performance.
    • Compared to its peers, Regeneron's valuation is generally in line with VRTX but higher than AMGN. This suggests that investors are willing to pay a higher premium for Regeneron's growth potential and strong financial performance.
    • Potential catalysts for Regeneron's stock price include the approval of new products, expansion of existing product indications, successful M&A activity, and continued strong financial performance.

  7. Price Performance:

    • Regeneron's stock price has generally outperformed the Health Care Select Sector SPDR Fund (XLV) over the past three years, with particularly strong performance in the 1-year and 2-year periods. However, REGN underperformed VRTX in the 3-year period, likely due to VRTX's strong performance in the early part of the period.
    • Regeneron's stock price has exhibited higher volatility than XLV, indicating a greater degree of price fluctuations. This suggests that REGN's stock price may be more susceptible to market swings and investor sentiment.
    • Regeneron's beta value consistently below 1 indicates that the stock is less volatile than the overall market. This suggests that REGN's stock price is less sensitive to broad market movements, potentially making it a more stable investment option.

  8. Future Outlook:

    • Regeneron's management team has provided positive guidance for the future, with expectations for continued revenue growth and strong financial performance. The company is investing heavily in R&D and commercialization to support the growth of its product portfolio and expand its market reach.
    • Analyst estimates for Regeneron's future performance are generally positive, with expectations for continued revenue growth and strong earnings. The consensus among analysts is that Regeneron is well-positioned for continued success in the biotechnology industry.

  9. Summary:

    • Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company with a strong financial position, characterized by high profitability, robust liquidity, and low debt levels. The company's revenue growth is driven by the success of its key products, EYLEA HD and Dupixent, and its expansion into new markets.
    • Regeneron is investing heavily in R&D and commercialization, which is driving the increase in operating expenses and leading to a decline in profitability. However, the company's strong financial position and robust cash flow provide it with the flexibility to continue investing in growth opportunities.
    • Regeneron faces several risks and threats, including dependence on a few key products, intense competition, regulatory challenges, and legal and compliance risks. However, the company's strong track record of innovation and execution, coupled with its robust pipeline, suggests that it is well-positioned to navigate these challenges and achieve continued success.
    • Regeneron's valuation is currently high, reflecting investor confidence in the company's growth potential and strong financial performance. The company's stock price has generally outperformed the broader healthcare sector and its peers, but it has exhibited higher volatility than its benchmark and peers.
    • Overall, Regeneron appears to be a well-positioned biotechnology company with strong growth potential and a solid financial foundation. However, investors should be aware of the company's dependence on a few key products, intense competition, and regulatory challenges.
Peer fundamentals 
Fundamentals
Insights
  • Regeneron is a leading biotechnology company with a strong financial position, characterized by high profitability, robust liquidity, and low debt levels.
  • The company's revenue growth is driven by the success of its key products, EYLEA HD and Dupixent, and its expansion into new markets.
  • Regeneron is investing heavily in R&D and commercialization, which is driving the increase in operating expenses and leading to a decline in profitability.
  • The company's cash flow from operations is decreasing, which could be a concern if it continues to decline.
  • Regeneron's financial flexibility will allow it to continue to pursue strategic opportunities and return capital to shareholders.
  • Key risks include the company's dependence on a few key products, intense competition in its key therapeutic areas, and the potential impact of increasing debt levels on its financial leverage and debt service coverage.
Analysis
  • Revenue - Regeneron's revenue is increasing, driven by the successful launch of EYLEA HD and the continued growth of Dupixent. - The company's revenue growth is outpacing the industry average, suggesting that it is gaining market share. - The company's revenue growth is expected to continue in the coming quarters, driven by the continued success of its key products and the potential approval of new products.
    • Profitability
      • Regeneron's profitability is strong, with a high return on assets and return on equity.
      • The company's profitability is declining, but it remains profitable.
      • The company's profitability is significantly higher than the industry average, suggesting that it is a more efficient operator.
    • Liquidity
      • Regeneron has a strong liquidity position, with a high current ratio and quick ratio.
      • The company's liquidity is slightly decreasing, but it remains strong.
      • The company's liquidity is slightly lower than the industry average, but it is still considered strong.
    • Solvency
      • Regeneron's solvency is strong, with a low debt-to-equity ratio and a high debt service coverage ratio.
      • The company's solvency is slightly decreasing, but it remains strong.
      • The company's solvency is significantly better than the industry average, suggesting that it is a more financially stable company.
    • Operational Efficiency
      • Regeneron's efficiency is high, with a high return on assets and return on equity.
      • The company's efficiency is slightly decreasing, but it remains high.
      • The company's efficiency is significantly higher than the industry average, suggesting that it is a more efficient operator.
    • Cash Flow Analysis
      • Regeneron's cash flow from operations is decreasing, which could be a concern.
      • The company's free cash flow is decreasing, which could impact its ability to invest in growth opportunities or return capital to shareholders.
      • The company's cash flow from investing activities is decreasing, which could indicate a shift in its investment strategy.
      • The company's cash flow from financing activities is increasing, which could be a sign of increased borrowing or share repurchases.
    • Risk Factors
      • Regeneron's dependence on the success of a few key products could pose a risk.
      • The company faces intense competition in its key therapeutic areas.
      • The company's increasing debt levels could impact its financial leverage and debt service coverage.
      • The company's declining free cash flow could impact its ability to invest in growth opportunities or return capital to shareholders.
    • Future Outlook
      • Regeneron's future prospects are positive, driven by its strong revenue growth, robust pipeline, and strong financial position.
      • The company's profitability is expected to remain strong, but it may face pressure from increasing operating expenses.
      • The company's cash flow is expected to be impacted by its investments in R&D and commercialization.
      • The company's financial flexibility will allow it to continue to pursue strategic opportunities and return capital to shareholders.
Most recent earnings report
Financial statements 
All public filings
Comparative Analysis
Benchmarks (as of 2024-08-20)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison:
    • REGN has consistently outperformed XLV across all historical periods, demonstrating strong performance relative to the broader healthcare sector. This outperformance is particularly notable in the longer-term periods, with REGN exceeding XLV by 73.22% over two years and 59.82% over three years.
    • The consistency of REGN's outperformance suggests that the company's growth strategy and product portfolio have been successful in driving shareholder value.
  • Risk and Return Analysis:
    • REGN has delivered higher annualized returns than XLV across all periods, indicating a strong track record of growth and profitability. This suggests that REGN has been able to generate significant returns for investors while navigating the healthcare market.
    • REGN has exhibited higher annualized volatility than XLV, indicating a greater degree of price fluctuations. This suggests that REGN's stock price may be more susceptible to market swings and investor sentiment.
    • REGN's maximum drawdown of 25.78% in Q2 2022 is significantly higher than XLV's maximum drawdown of 16.06% in the same quarter. This indicates that REGN's stock price is more vulnerable to significant declines during market downturns, highlighting a higher risk profile compared to XLV.
  • Risk-Adjusted Performance:
    • REGN's Sharpe Ratio has been generally lower than XLV's, suggesting that XLV has offered better risk-adjusted returns over the period. This implies that XLV has been able to generate higher returns for investors relative to the risk taken.
    • REGN's beta value consistently below 1 indicates that the stock is less volatile than the overall market. This suggests that REGN's stock price is less sensitive to broad market movements, potentially making it a more stable investment option.
  • Overall Assessment:
    • REGN has demonstrated strong performance, consistently outperforming XLV across all historical periods. However, this performance comes with a higher risk profile, as evidenced by its higher volatility and maximum drawdown.
    • While REGN's lower beta suggests a lower sensitivity to market movements, its Sharpe Ratio has been consistently lower than XLV's, indicating that XLV has offered better risk-adjusted returns.
    • Investors seeking high growth potential may find REGN attractive, but they should be aware of the associated risks. Investors seeking a more stable and risk-averse investment may prefer XLV, which has demonstrated better risk-adjusted returns.
    • It is important to note that past performance is not indicative of future results. Investors should conduct thorough due diligence and consider their individual risk tolerance and investment goals before making any investment decisions.
Peers Price History(as of 2024-09-04)
Vertex Pharmaceuticals, Inc. (VRTX)Amgen, Inc. (AMGN)
  • Performance Comparison:
    • REGN has generally outperformed both VRTX and AMGN over the past three years, with particularly strong performance in the 1-year and 2-year periods. However, REGN underperformed VRTX in the 3-year period, likely due to VRTX's strong performance in the early part of the period.
    • REGN's performance has been relatively consistent compared to its peers, with a few periods of underperformance.
  • Risk and Return Analysis:
    • REGN has provided higher annualized returns than AMGN in all periods, but it has underperformed VRTX in the 3-year period.
    • REGN has exhibited lower annualized volatility than VRTX in most periods, but it has been more volatile than AMGN.
    • REGN's maximum drawdown of 25.78% is lower than VRTX's maximum drawdown of 35.89% but higher than AMGN's maximum drawdown of 24.86%. This suggests that REGN has a moderate risk profile compared to its peers.
  • Risk-Adjusted Performance:
    • REGN has generally offered a better risk-adjusted return than VRTX and AMGN, as indicated by its higher Sharpe Ratio. However, there have been periods where VRTX has outperformed REGN on a risk-adjusted basis.
    • REGN's beta value suggests that it is slightly more sensitive to market movements than AMGN but less sensitive than VRTX.
  • Overall Assessment:
    • REGN has demonstrated strong historical performance, outperforming its peers in most periods. However, its performance has been less consistent than AMGN's.
    • REGN has a moderate risk profile, with lower volatility and drawdowns than VRTX but higher than AMGN.
    • REGN's higher Sharpe Ratio suggests that it offers better risk-adjusted returns than its peers.
    • REGN's beta indicates that it is slightly more sensitive to market movements than AMGN but less sensitive than VRTX.
    • Overall, REGN appears to be a solid investment option with strong performance and a moderate risk profile. However, investors should consider the company's recent volatility and its underperformance compared to VRTX in the 3-year period.
Peers Fundamentals(as of 2024-06-30)
Vertex Pharmaceuticals, Inc. (VRTX)Amgen, Inc. (AMGN)

  1. Market Position and Size:

    • REGN has a market capitalization of 129987.0 million, placing it in the middle of the peer group in terms of size, larger than VRTX but smaller than AMGN.
    • REGN's market cap is significantly larger than VRTX's despite having lower revenue, EBITDA, and net income, suggesting the market may be valuing REGN's future growth potential or profitability more highly.
    • However, REGN's market cap is significantly smaller than AMGN's, despite having comparable revenue and higher profitability, suggesting the market may be valuing AMGN's larger size, established product portfolio, or overall financial stability more highly.

  2. Profitability and Efficiency:

    • REGN exhibits strong profitability metrics, significantly outperforming both peers and industry averages in Gross Profit Margin, EBITDA Margin, and Net Profit Margin.
    • This strong profitability is particularly notable considering its smaller size compared to AMGN, highlighting its potential for continued growth and value creation.
    • REGN also demonstrates strong efficiency in generating returns, with high ROA, ROTE, ROTC, and ROIC, suggesting effective utilization of assets and capital to generate returns for investors.

  3. Financial Health and Stability:

    • REGN exhibits a strong liquidity position and a moderate level of debt compared to peers and industry averages.
    • Its high Current Ratio and Quick Ratio indicate ample liquid assets to cover short-term liabilities, suggesting a strong ability to meet immediate financial obligations.
    • Its moderate Total Debt to Total Equity Ratio and Debt / EBITDA ratio suggest a balanced approach to financing operations and a healthy financial position.

  4. Valuation and Market Perception:

    • REGN exhibits a relatively high valuation compared to peers and industry averages, reflecting the market's perception of its growth potential and profitability.
    • Its EV/Sales and EV/EBITDA ratios suggest a premium valuation compared to AMGN but a discount compared to VRTX and the industry average.
    • This mixed valuation picture likely reflects the market's balancing of REGN's strong profitability and growth potential against its smaller size and potentially lower perceived financial stability compared to AMGN.

  5. Cash Flow and Capital Management:

    • REGN demonstrates strong cash flow generation capabilities relative to its size, peers, and industry norms.
    • Its substantial free cash flow generation, coupled with its moderate capital expenditures, indicates a healthy financial position and a strong ability to fund future growth initiatives.

  6. Growth and Future Prospects:

    • REGN exhibits a mixed growth profile compared to the peer group average, with both areas of strength and weakness.
    • REGN shows consistently higher growth in free cash flow and book value per share, suggesting strong returns for shareholders and the financial resources to support future growth initiatives.
    • However, REGN's lagging growth in sales revenue, EBITDA, and net income compared to peers suggests potential challenges in expanding its product portfolio or market reach.

  7. Potential for Investment:

    • REGN presents an interesting investment opportunity, characterized by its strong profitability, efficient operations, and robust cash flow generation.
    • Its smaller size compared to AMGN may limit its market share and valuation, but its strong financial performance suggests a potential for continued growth and value creation.
    • Investors seeking exposure to the biotechnology sector with a focus on profitability and efficiency may find REGN attractive.

  8. Key Risks and Considerations:

    • REGN's lagging revenue growth compared to peers could potentially limit its ability to compete effectively in the long term.
    • Its valuation may be constrained by its smaller size and potentially lower perceived financial stability compared to AMGN.
    • REGN's cash flow generation may be subject to volatility, potentially due to factors such as product launches, regulatory approvals, or changes in operating expenses.

  9. Overall Assessment:

    • REGN exhibits strong overall financial health and performance relative to its peer group and industry averages, taking into account its market position and size.
    • Its strong profitability, efficient returns generation, and robust cash flow generation capabilities suggest a healthy financial position and a strong ability to manage its financial resources effectively.
    • While REGN's revenue growth may be lagging behind its peers, its strong profitability and cash flow generation provide a solid foundation for future growth.
    • Its moderate debt levels and strong liquidity position further enhance its financial stability.
    • Overall, REGN's financial health is characterized by a strong foundation of profitability, efficiency, and cash flow generation, which positions it favorably for continued growth and value creation.